BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-biroulet L. Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease: A 14-Year Single-Center Experience. Inflammatory Bowel Diseases 2017;23:976-85. [DOI: 10.1097/mib.0000000000001072] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:1298-308. [PMID: 34559428 DOI: 10.1111/apt.16605] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Blesl A, Binder L, Högenauer C, Wenzl H, Borenich A, Pregartner G, Berghold A, Mestel S, Kump P, Baumann-Durchschein F, Petritsch W. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther 2021;54:667-77. [PMID: 34151449 DOI: 10.1111/apt.16478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Masui S, Yonezawa A, Momo K, Nakagawa S, Itohara K, Imai S, Nakagawa T, Matsubara K. Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study. Biol Pharm Bull 2022;45:323-32. [PMID: 35228398 DOI: 10.1248/bpb.b21-00906] [Reference Citation Analysis]
4 Zhao M, Sall Jensen M, Knudsen T, Kelsen J, Coskun M, Kjellberg J, Burisch J. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther 2021. [PMID: 34881439 DOI: 10.1111/apt.16723] [Reference Citation Analysis]
5 Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep 2020;22:36. [PMID: 32542562 DOI: 10.1007/s11894-020-00773-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang TH. An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn's Disease. Biologics 2021;15:237-45. [PMID: 34163137 DOI: 10.2147/BTT.S310076] [Reference Citation Analysis]
7 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
8 Laganà B, Zullo A, Scribano ML, Chimenti MS, Migliore A, Picchianti Diamanti A, Lorenzetti R, Scolieri P, Ridola L, Ortona E, Pierdominici M, Bruzzese V. Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. Front Pharmacol 2019;10:47. [PMID: 30745872 DOI: 10.3389/fphar.2019.00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Mühl L, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, Zundler S. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol 2021;21:33. [PMID: 33482730 DOI: 10.1186/s12876-021-01604-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]